Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Brands Invests $111m To Boost Advertising From Market Research

This article was originally published in The Tan Sheet

Executive Summary

Prestige Brands supports leading brands including Monistat and Dramamine with promotional campaigns stemming from research into consumer preferences, says sales and marketing head Timothy Connors. With $111m ad spend, it aims to become a “preeminent marketing and sales” firm.

You may also be interested in...



Prestige Routes Summer’s Eve, Dentek ‘Brand Building’ On Dramamine Path

Prestige Consumer Healthcare is launching two products under Summer’s Eve brand for feminine hygiene during menstruation and professional-grade mouth guard under Dentek, as well as other products that will help grow "leading but under-invested” brands.

In Brief: Prestige Buys Insight, Quarterly Earnings For MJN And Colgate, Bio-Recovery Warned On Claims

Prestige acquires Insight Pharmaceuticals; Product relaunches boost Novartis’ consumer sales; Colgate’s N.A. sales inch up; Mead Johnson sales up 7%; and Bio-Recovery makes drug claims.

Prestige Brands Revs Up Goody’s, BC Brands

Prestige Brands is promoting Goody’s Headache Relief Shot through a deal with NASCAR and its first TV ad on ESPN. Goody’s has paved the way for further expansion into convenience stores, the company says during a sales and earnings call Nov. 7.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel